1. A pharmacologist is explaining to trainees why cabergoline simultaneously delivers therapeutic benefit in prolactinoma and carries a risk of cardiac valvulopathy, even though both effects originate from the same molecule. Which of the following statements correctly integrates the two distinct receptor mechanisms responsible for these opposing clinical consequences?
A) Both the therapeutic prolactin suppression and the valvulopathy arise from D2 receptor (D2R) activation: D2R on lactotrophs lowers prolactin, and the same D2R on cardiac valve fibroblasts drives fibrosis, so the two effects are inseparable manifestations of a single receptor pathway.
B) The therapeutic effect arises from serotonin 5-HT2B receptor activation on lactotrophs that lowers prolactin, while the valvulopathy arises from D2R activation on cardiac valve fibroblasts; the two effects are mediated by swapped receptor roles at the two tissues.
C) The therapeutic effect arises from D2R activation on lactotrophs — a Gi-coupled pathway that lowers cyclic AMP (cAMP) and suppresses prolactin — while the valvulopathy arises from a pharmacologically distinct action at serotonin 5-HT2B receptors on cardiac valve fibroblasts that stimulates fibroblast proliferation and collagen deposition; the benefit and the harm are therefore mediated by two different receptors, which is why cumulative dose governs valve risk without contributing to the therapeutic mechanism.
D) Both effects arise from 5-HT2B receptor activation: 5-HT2B on lactotrophs suppresses prolactin therapeutically, and 5-HT2B on cardiac fibroblasts drives valvulopathy, so the two effects share one receptor and cannot be pharmacologically separated.
E) The therapeutic effect and the valvulopathy both arise from a single Gi-coupled receptor expressed in both tissues, and the difference is purely one of tissue drug concentration rather than receptor identity.
ANSWER: C
Rationale:
This question integrates two separate receptor mechanisms that coexist in a single molecule. Cabergoline's therapeutic benefit in prolactinoma comes from agonism at D2 receptors (D2R) on lactotrophs: D2R is Gi-coupled, so activation inhibits adenylyl cyclase, lowers cyclic AMP (cAMP), and suppresses prolactin transcription and secretion. Its valvulopathy risk comes from a pharmacologically distinct action at serotonin 5-HT2B receptors on cardiac valve interstitial fibroblasts, where agonism stimulates fibroblast proliferation and collagen deposition, producing leaflet thickening and regurgitation. Because these are two different receptors in two different tissues, the harm scales with cumulative drug exposure while contributing nothing to the therapeutic mechanism — which is precisely why higher-dose, longer-duration regimens raise valve risk and why surveillance is dose-driven.
Option A: Option A is incorrect because the valvulopathy is not a D2R effect; valve fibrosis is mediated by 5-HT2B receptors, so the two effects do not arise from a single D2R pathway and are in fact separable in principle by receptor selectivity.
Option B: Option B is incorrect because it swaps the receptor roles: prolactin suppression is D2R-mediated (not 5-HT2B), and valvulopathy is 5-HT2B-mediated (not D2R); the option inverts both assignments.
Option D: Option D is incorrect because prolactin suppression is not a 5-HT2B effect; the therapeutic action is D2R-mediated, so the two effects do not share the 5-HT2B receptor.
Option E: Option E is incorrect because the benefit and harm are mediated by two distinct receptors (D2R and 5-HT2B), not a single Gi-coupled receptor differing only by tissue concentration; receptor identity, not merely drug concentration, distinguishes the two effects.
2. A 42-year-old man with a 3.5 cm sellar mass and visual field loss had an initially reported serum prolactin of 45 ng/mL. After a 1:100 serial dilution, the prolactin is found to be 6,200 ng/mL. Integrating the assay finding with the expected biology of the lesion, which of the following best predicts the appropriate treatment course and its rationale?
A) The diluted result confirms a non-functioning adenoma with stalk-effect hyperprolactinemia; transsphenoidal surgery is the definitive first step, and dopamine agonists will not shrink this tumor.
B) The diluted result confirms a clinically nonfunctioning gonadotroph adenoma; because the prolactin elevation is secondary, the patient should receive radiotherapy rather than a dopamine agonist.
C) The diluted result indicates macroprolactinemia from big-big prolactin; no treatment is needed because macroprolactin is biologically inactive, and the mass should simply be observed.
D) The diluted result is an assay artifact that should be disregarded; the true prolactin is the originally reported 45 ng/mL, and the mass should be managed as a non-functioning adenoma.
E) The diluted result unmasks a true very high prolactin consistent with a macroprolactinoma that was producing a falsely low value through the hook effect; first-line treatment is a dopamine agonist such as cabergoline, which is expected to both normalize prolactin and reduce tumor volume, often relieving the visual compromise and avoiding surgery.
ANSWER: E
Rationale:
This question integrates the assay phenomenon (hook effect) with prolactinoma treatment biology. The original low prolactin of 45 ng/mL in the presence of a large sellar mass is the classic signature of the hook effect, in which extremely high prolactin saturates the immunometric assay and yields a falsely low value; serial dilution unmasks the true concentration of 6,200 ng/mL, confirming a macroprolactinoma. Because macroprolactinomas retain D2 receptor expression in most cases, the appropriate first-line treatment is a dopamine agonist such as cabergoline, which is expected to normalize prolactin and produce tumor volume reduction in the large majority of patients — often relieving mass effect including visual compromise and avoiding the need for surgery.
Option A: Option A is incorrect because the very high diluted prolactin establishes a macroprolactinoma, not a non-functioning adenoma with stalk effect; stalk-effect hyperprolactinemia produces only modest elevations (generally below 150 to 200 ng/mL), not values in the thousands, and dopamine agonists do shrink macroprolactinomas.
Option B: Option B is incorrect because the markedly elevated diluted prolactin indicates a prolactin-secreting macroadenoma rather than a nonfunctioning gonadotroph adenoma, and medical therapy with a dopamine agonist — not primary radiotherapy — is first-line.
Option C: Option C is incorrect because macroprolactinemia (big-big prolactin) is associated with elevated measured prolactin that overestimates bioactive hormone and does not explain a falsely low initial value later found to be very high on dilution; the dilution result here reflects a true high prolactin from a macroprolactinoma requiring treatment, not inert macroprolactin.
Option D: Option D is incorrect because the diluted value is the accurate measurement, not an artifact to disregard; the artifact was the falsely low undiluted value caused by assay saturation, and managing this as a non-functioning adenoma would miss a treatable macroprolactinoma.
3. A 45-year-old woman with Cushing disease has a partial response to pasireotide monotherapy — her urinary free cortisol (UFC) has fallen by about 40% but remains above normal. Her endocrinologist considers adding cabergoline. Integrating the receptor biology of the two drugs at the corticotroph adenoma, which of the following best explains the rationale for combining them?
A) Cabergoline and pasireotide both act on somatostatin receptor subtype 5 (SSTR5), so adding cabergoline simply increases SSTR5 occupancy and produces a purely additive effect at the same receptor.
B) Pasireotide suppresses ACTH through somatostatin receptor subtype 5 (SSTR5), while cabergoline suppresses ACTH through dopamine D2 receptors (D2R); because corticotroph adenomas can express both receptor types, engaging two independent inhibitory pathways can produce additive or complementary ACTH suppression in a tumor that is only partially controlled by either agent alone.
C) Cabergoline blocks adrenal steroidogenesis through CYP11B1 inhibition while pasireotide acts at the pituitary, so the combination works by attacking cortisol synthesis at two enzymatic levels of the adrenal cortex.
D) Pasireotide acts at the corticotroph and cabergoline acts as a glucocorticoid receptor antagonist at peripheral tissues, so the combination both lowers ACTH and blocks residual cortisol signaling.
E) The two drugs are pharmacologically redundant because both ultimately lower cortisol, so adding cabergoline provides no mechanistic advantage and the combination should not be used.
ANSWER: B
Rationale:
This question integrates the distinct corticotroph receptor pathways targeted by two pituitary-directed agents. Pasireotide suppresses ACTH secretion by activating somatostatin receptor subtype 5 (SSTR5), the predominant somatostatin receptor on corticotroph adenomas. Cabergoline suppresses ACTH through a different receptor — the dopamine D2 receptor (D2R) — which corticotroph adenomas also express with variable density. Because the two drugs engage two independent inhibitory pathways converging on the same cell, combining them can produce additive or complementary ACTH suppression in a tumor only partially controlled by either agent alone; this combination strategy is used clinically in partial responders.
Option A: Option A is incorrect because cabergoline does not act on SSTR5; it acts on D2R, so the combination engages two different receptors rather than increasing occupancy at a single shared receptor.
Option C: Option C is incorrect because cabergoline does not inhibit adrenal CYP11B1 or block steroidogenesis; it is a pituitary-directed dopamine agonist, so the combination is not an adrenal two-enzyme blockade.
Option D: Option D is incorrect because cabergoline is not a glucocorticoid receptor antagonist; that mechanism belongs to mifepristone, and cabergoline instead suppresses ACTH at the corticotroph through D2R.
Option E: Option E is incorrect because the drugs are not redundant; they act through distinct receptors (SSTR5 versus D2R) and can therefore provide complementary suppression, which is the mechanistic basis for combining them in partial responders.
4. A 50-year-old man on pasireotide for Cushing disease develops hyperglycemia. His physician must choose between a sulfonylurea and a glucagon-like peptide-1 (GLP-1) receptor agonist. Integrating pasireotide's effect on the pancreatic islet with the signaling pathways of each drug class, which of the following best explains why the GLP-1 receptor agonist is expected to retain efficacy while the sulfonylurea is blunted?
A) Pasireotide activates somatostatin receptors on pancreatic beta cells, which are Gi-coupled and lower cyclic AMP (cAMP), thereby suppressing insulin secretion at a step downstream of the sulfonylurea's site of action; GLP-1 receptor agonists act through Gs-coupled GLP-1 receptors that raise cAMP and stimulate glucose-dependent insulin secretion while also suppressing glucagon, partially counteracting the somatostatin-driven cAMP reduction and so retaining efficacy that the sulfonylurea loses.
B) Sulfonylureas and GLP-1 receptor agonists act through the identical beta-cell pathway, but the GLP-1 receptor agonist reaches a higher intracellular concentration, allowing it to overcome somatostatin receptor inhibition by mass action alone.
C) Pasireotide raises cAMP in beta cells, which enhances sulfonylurea-stimulated insulin secretion; the GLP-1 receptor agonist is preferred only because it additionally promotes weight loss, not because of any signaling difference.
D) GLP-1 receptor agonists suppress insulin secretion through the same Gi-coupled pathway as pasireotide, while sulfonylureas stimulate it; the GLP-1 receptor agonist is preferred because lowering insulin reduces pasireotide-related hyperglycemia.
E) The sulfonylurea is blunted because pasireotide blocks the GLP-1 receptor directly, whereas the GLP-1 receptor agonist bypasses this blockade by acting on the sulfonylurea receptor instead.
ANSWER: A
Rationale:
This question integrates pasireotide's islet pharmacology with the contrasting signaling of two antidiabetic classes. Pasireotide activates somatostatin receptors on pancreatic beta cells; these receptors are Gi-coupled, so they inhibit adenylyl cyclase, lower cyclic AMP (cAMP), and suppress insulin secretion. Sulfonylureas stimulate insulin release by closing ATP-sensitive potassium channels, but the somatostatin-driven reduction in cAMP acts downstream and dampens the resulting insulin exocytosis, blunting sulfonylurea efficacy. GLP-1 receptor agonists, by contrast, act through Gs-coupled GLP-1 receptors that raise cAMP and stimulate glucose-dependent insulin secretion while suppressing glucagon; by raising cAMP, they directly counteract the somatostatin-driven cAMP reduction, so they retain efficacy where the sulfonylurea is impaired. This signaling logic is the mechanistic basis for preferring GLP-1 receptor agonists in pasireotide-induced hyperglycemia.
Option B: Option B is incorrect because sulfonylureas and GLP-1 receptor agonists do not act through an identical pathway; they engage different targets (the sulfonylurea receptor/KATP channel versus the Gs-coupled GLP-1 receptor), and the advantage is mechanistic rather than a matter of mass-action concentration.
Option C: Option C is incorrect because pasireotide lowers rather than raises beta-cell cAMP, so it suppresses rather than enhances sulfonylurea-stimulated secretion; the GLP-1 receptor agonist's preference rests on a signaling difference, not solely on weight effects.
Option D: Option D is incorrect because GLP-1 receptor agonists stimulate (not suppress) insulin secretion through a Gs-coupled, cAMP-raising pathway; they do not share pasireotide's Gi-coupled inhibitory mechanism, and the benefit is increased glucose-dependent insulin secretion, not reduced insulin.
Option E: Option E is incorrect because pasireotide does not block the GLP-1 receptor, and GLP-1 receptor agonists do not act on the sulfonylurea receptor; the two drug classes act at distinct receptors, and the explanation lies in opposing effects on cAMP, not receptor cross-blockade.
5. A 48-year-old woman with Cushing disease is undergoing stepwise metyrapone dose escalation. Integrating the enzyme block with the downstream mineralocorticoid pathway and the feedback response, which of the following best predicts the trajectory of her cortisol, ACTH, blood pressure, and potassium as the dose is increased toward full effect?
A) As the dose increases, cortisol falls, ACTH falls in parallel, and blood pressure and potassium remain unchanged because metyrapone blocks only the glucocorticoid pathway and spares mineralocorticoid synthesis entirely.
B) As the dose increases, cortisol rises, ACTH falls, blood pressure falls, and potassium rises, because metyrapone's enzyme block diverts precursors away from both cortisol and mineralocorticoids.
C) As the dose increases, cortisol and aldosterone both fall, ACTH falls, blood pressure falls, and potassium rises, because metyrapone inhibits aldosterone synthase and produces aldosterone deficiency.
D) As the dose increases, cortisol falls while ACTH rises (loss of cortisol negative feedback); the CYP11B1 block also causes 11-deoxycorticosterone (DOC) to accumulate, and because ACTH stimulation drives more precursor through the blocked pathway, DOC-mediated mineralocorticoid activity tends to increase, raising blood pressure and lowering potassium even as cortisol falls.
E) As the dose increases, cortisol falls, ACTH rises, and blood pressure and potassium are unaffected because DOC is not mineralocorticoid-active and cannot influence renal sodium or potassium handling.
ANSWER: D
Rationale:
This question integrates the CYP11B1 enzyme block, the HPA feedback loop, and downstream mineralocorticoid physiology to predict a multi-parameter trajectory. As metyrapone is escalated, it increasingly inhibits CYP11B1 (11-beta-hydroxylase), so cortisol falls. Falling cortisol removes negative feedback, so ACTH rises. The same CYP11B1 block prevents conversion of 11-deoxycorticosterone (DOC) to corticosterone, causing DOC to accumulate; the rising ACTH simultaneously drives more steroid precursor into the adrenal pathway, increasing DOC production further. Because DOC is a weak but real mineralocorticoid, its accumulation activates renal mineralocorticoid receptors, promoting sodium retention (raising blood pressure) and potassium excretion (lowering potassium). Thus the integrated prediction is falling cortisol, rising ACTH, rising blood pressure, and falling potassium — the characteristic pattern of effective metyrapone therapy.
Option A: Option A is incorrect because metyrapone does not spare the mineralocorticoid pathway; the CYP11B1 block causes DOC accumulation that alters blood pressure and potassium, and ACTH rises rather than falls as cortisol declines.
Option B: Option B is incorrect because cortisol falls (not rises) with effective CYP11B1 blockade, and the mineralocorticoid effect of accumulating DOC raises blood pressure and lowers potassium rather than the reverse.
Option C: Option C is incorrect because metyrapone selectively inhibits CYP11B1, not aldosterone synthase (CYP11B2); the aldosterone-deficiency pattern of hypotension and hyperkalemia/hypokalemia from aldosterone loss describes osilodrostat, not metyrapone.
Option E: Option E is incorrect because DOC is mineralocorticoid-active; its accumulation does influence renal sodium and potassium handling, producing hypertension and hypokalemia, so blood pressure and potassium are not unaffected.
6. A 51-year-old woman on osilodrostat for Cushing disease presents with fatigue, nausea, light-headedness on standing, hypotension, hyponatremia, and hypokalemia. The clinical team must determine whether these findings represent cortisol over-suppression (adrenal insufficiency) or the drug's aldosterone-pathway effect, since the management differs. Integrating osilodrostat's dual enzyme inhibition with adrenal physiology, which of the following best explains the findings and the correct interpretation?
A) The findings are purely an aldosterone-synthase effect with no cortisol component: hyponatremia and hypotension arise solely from CYP11B2 inhibition, and cortisol levels are necessarily normal, so glucocorticoid assessment is unnecessary.
B) The findings indicate mineralocorticoid excess from 11-deoxycorticosterone (DOC) accumulation, identical to metyrapone, so the appropriate response is to add a mineralocorticoid receptor antagonist.
C) Osilodrostat inhibits both CYP11B1 (lowering cortisol) and CYP11B2 (lowering aldosterone); excessive CYP11B1 inhibition can produce cortisol over-suppression with adrenal insufficiency (fatigue, nausea, hypotension, hyponatremia), while CYP11B2 inhibition reduces aldosterone and can independently contribute to hypotension and electrolyte disturbance — so the overlapping picture requires assessing for glucocorticoid insufficiency and treating with hydrocortisone if cortisol is over-suppressed, alongside electrolyte and blood pressure management.
D) The findings reflect DOC-mediated hypertension that has been masked by concurrent diuretic use; osilodrostat raises blood pressure, so the hypotension must be iatrogenic from another medication.
E) The findings indicate that osilodrostat has induced a hyperglycemic crisis through somatostatin receptor activation, and the hypotension reflects osmotic diuresis rather than any adrenal steroid effect.
ANSWER: C
Rationale:
This question integrates osilodrostat's dual enzyme inhibition with adrenal physiology to disentangle two overlapping mechanisms. Osilodrostat inhibits CYP11B1 (11-beta-hydroxylase), lowering cortisol, and also inhibits CYP11B2 (aldosterone synthase), lowering aldosterone. Excessive CYP11B1 inhibition can over-suppress cortisol and produce adrenal insufficiency — fatigue, nausea, hypotension, and hyponatremia. Independently, CYP11B2 inhibition reduces aldosterone, which can contribute to hypotension and to electrolyte disturbances. Because the two effects overlap clinically, the correct approach is to assess for glucocorticoid insufficiency and administer hydrocortisone if cortisol is over-suppressed, while concurrently managing electrolytes and blood pressure. Recognizing both contributing mechanisms is essential because missing cortisol over-suppression could be dangerous.
Option A: Option A is incorrect because the picture is not purely an aldosterone-synthase effect; cortisol over-suppression from CYP11B1 inhibition is a real and potentially dangerous contributor, so glucocorticoid assessment is necessary rather than unnecessary.
Option B: Option B is incorrect because osilodrostat does not produce the DOC-driven mineralocorticoid excess characteristic of metyrapone; its CYP11B2 inhibition lowers aldosterone, producing hypotension rather than hypertension, so a mineralocorticoid receptor antagonist is not the appropriate response.
Option D: Option D is incorrect because osilodrostat lowers aldosterone and tends to cause hypotension, not DOC-mediated hypertension; attributing the hypotension solely to another medication misreads the drug's mechanism.
Option E: Option E is incorrect because osilodrostat is a steroidogenesis inhibitor, not a somatostatin analog; it does not act through somatostatin receptors or produce a hyperglycemic crisis by that mechanism, and the hypotension reflects adrenal steroid effects rather than osmotic diuresis.
7. A 62-year-old man with adrenocortical carcinoma and cortisol excess is anticoagulated with warfarin and is started on mitotane. Integrating mitotane's enzyme-induction profile, warfarin enantiomer pharmacology, and the underlying coagulation state of hypercortisolism, which of the following best characterizes the net thrombotic risk and the required management?
A) Mitotane induces CYP2C9 and CYP3A4, accelerating clearance of both warfarin enantiomers (the active S-warfarin via CYP2C9 and R-warfarin via CYP3A4); this lowers warfarin exposure and the INR, reducing anticoagulant effect at the same time that cortisol excess already promotes a hypercoagulable state — so net thrombotic risk rises, and warfarin doses must be increased substantially with frequent INR monitoring until a new stable therapeutic level is reached.
B) Mitotane inhibits CYP2C9, raising S-warfarin levels and the INR; combined with the bleeding tendency of cortisol excess, net hemorrhage risk rises, and warfarin doses must be reduced.
C) Mitotane has no effect on warfarin metabolism because warfarin is cleared unchanged renally; the only relevant factor is the hypercoagulable state of cortisol excess, which is managed by adding aspirin rather than adjusting warfarin.
D) Mitotane induces CYP2C9 and lowers the INR, but because cortisol excess produces a bleeding diathesis, the two effects cancel out and no warfarin dose change or extra monitoring is required.
E) Mitotane raises warfarin levels through plasma protein displacement from adipose tissue, increasing the INR; because cortisol excess also raises bleeding risk, warfarin should be discontinued entirely.
ANSWER: A
Rationale:
This question integrates three elements: mitotane's enzyme induction, warfarin enantiomer-specific metabolism, and the coagulation physiology of hypercortisolism. Mitotane is a potent inducer of CYP3A4 and CYP2B6 and also induces CYP2C9. Warfarin is administered as a racemate: the more potent S-enantiomer is metabolized chiefly by CYP2C9 and the R-enantiomer by CYP3A4. By inducing both enzymes, mitotane accelerates clearance of both enantiomers, lowering warfarin exposure and the INR and thereby reducing anticoagulant effect. Critically, this loss of anticoagulation occurs in a patient whose cortisol excess already creates a hypercoagulable, prothrombotic state — so the two effects compound rather than cancel, and net thrombotic risk rises. Management requires substantial warfarin dose increases (often 50% or more) with frequent INR monitoring (every 2 weeks) until a new stable therapeutic INR is achieved.
Option B: Option B is incorrect because mitotane induces rather than inhibits CYP2C9, so S-warfarin levels and the INR fall rather than rise; and hypercortisolism produces a hypercoagulable (thrombotic), not a bleeding, tendency, so the net risk is thrombosis and doses must increase, not decrease.
Option C: Option C is incorrect because warfarin is extensively metabolized by hepatic cytochrome P450 enzymes rather than cleared unchanged renally; mitotane's induction has a major effect on warfarin, and the management is warfarin dose adjustment with monitoring, not simply adding aspirin.
Option D: Option D is incorrect because the two effects do not cancel: mitotane lowering the INR and cortisol excess promoting hypercoagulability both push toward thrombosis, so dose increase and intensified monitoring are required.
Option E: Option E is incorrect because mitotane lowers warfarin levels through enzyme induction rather than raising them via adipose protein displacement, and discontinuing warfarin in a hypercoagulable patient would dangerously increase thrombotic risk.
8. A 56-year-old woman with Cushing syndrome on mifepristone is being followed for both efficacy and the emergence of adrenal insufficiency. Integrating mifepristone's receptor mechanism with the consequences for the HPA axis and for clinical monitoring, which of the following best explains why standard cortisol-based biochemical markers cannot be used for either purpose and what must be used instead?
A) Mifepristone lowers cortisol secretion, so a normal cortisol indicates efficacy and a low cortisol indicates adrenal insufficiency; cortisol therefore remains the central monitoring tool for both purposes.
B) Mifepristone suppresses ACTH, so a rising ACTH indicates loss of efficacy and a falling cortisol indicates adrenal insufficiency; both markers remain interpretable and should be followed serially.
C) Mifepristone blocks cortisol synthesis at the adrenal level, so UFC falls with efficacy; adrenal insufficiency is detected by a cosyntropin stimulation test, which remains valid during therapy.
D) Mifepristone lowers cortisol at target tissues but not in serum, so serum cortisol is unchanged and uninformative, while UFC falls and should be used to track efficacy; adrenal insufficiency is detected by a falling UFC.
E) Mifepristone is a glucocorticoid receptor (GR) antagonist that does not lower cortisol secretion; GR blockade removes cortisol's negative feedback, so ACTH and cortisol rise during therapy, making serum cortisol, UFC, and ACTH all uninterpretable for efficacy or for detecting adrenal insufficiency — instead, efficacy is judged by clinical and metabolic endpoints (glucose/HbA1c, blood pressure, weight, cushingoid features), and adrenal insufficiency is recognized clinically (hypotension, fatigue, nausea, hyponatremia) and treated empirically with high-dose hydrocortisone.
ANSWER: E
Rationale:
This question integrates mifepristone's receptor mechanism, its effect on the HPA feedback loop, and the resulting consequences for monitoring. Mifepristone is a glucocorticoid receptor (GR) antagonist that blocks cortisol action at target tissues without reducing cortisol secretion. Because GR blockade removes cortisol's negative feedback on the hypothalamus and pituitary, ACTH and cortisol both rise during therapy. As a result, serum cortisol, UFC, and ACTH are all uninterpretable — they cannot be used to judge efficacy (they rise even when the drug is working) or to detect adrenal insufficiency (a high cortisol does not exclude tissue-level glucocorticoid deficiency). Efficacy is therefore assessed by clinical and metabolic endpoints: glucose control and HbA1c (mifepristone is indicated for hyperglycemia in Cushing syndrome), blood pressure, weight, and resolution of cushingoid features. Adrenal insufficiency must be recognized on clinical grounds (hypotension, fatigue, nausea, hyponatremia) and treated empirically with high-dose hydrocortisone, with mifepristone discontinuation to restore normal feedback.
Option A: Option A is incorrect because mifepristone does not lower cortisol secretion; cortisol actually rises during therapy, so a normal or low cortisol cannot be used to gauge efficacy or diagnose adrenal insufficiency.
Option B: Option B is incorrect because mifepristone does not suppress ACTH; ACTH rises with GR blockade, so neither rising ACTH nor falling cortisol is an interpretable marker in this setting.
Option C: Option C is incorrect because mifepristone does not block adrenal cortisol synthesis (it is a receptor antagonist, not a steroidogenesis inhibitor), so UFC does not fall, and the cosyntropin stimulation test is not a reliable tool for detecting adrenal insufficiency during GR blockade.
Option D: Option D is incorrect because mifepristone does not lower UFC; UFC tends to rise with the overall increase in cortisol secretion, so it cannot track efficacy or detect adrenal insufficiency, and clinical rather than biochemical endpoints are required.
9. A 38-year-old woman with Cushing disease and hirsutism is started on ketoconazole while taking cyclosporine after a kidney transplant. Integrating ketoconazole's adrenal enzyme target with its hepatic cytochrome effect, which of the following best predicts the combined endocrine and drug-interaction consequences of this therapy?
A) Ketoconazole most potently inhibits CYP11B1, lowering cortisol but leaving androgens and hirsutism unchanged; it induces hepatic CYP3A4, lowering cyclosporine levels, so the cyclosporine dose must be increased.
B) Ketoconazole most potently inhibits CYP17A1 (17-alpha-hydroxylase/17,20-lyase), which participates in both cortisol and androgen synthesis, so it lowers cortisol and also reduces androgens — potentially improving hirsutism; separately, it is a strong hepatic CYP3A4 inhibitor, so it markedly raises cyclosporine levels and the cyclosporine dose must be reduced with trough monitoring.
C) Ketoconazole inhibits CYP17A1, raising both cortisol and androgens, worsening hirsutism; it also inhibits CYP3A4, lowering cyclosporine levels and requiring a cyclosporine dose increase.
D) Ketoconazole inhibits aldosterone synthase, lowering aldosterone and causing hypertension; it has no effect on cyclosporine because cyclosporine is not a CYP3A4 substrate.
E) Ketoconazole inhibits CYP17A1 and lowers cortisol, but androgen synthesis is independent of this enzyme, so hirsutism is unaffected; it induces CYP3A4, so cyclosporine levels fall and bleeding risk rises.
ANSWER: B
Rationale:
This question integrates ketoconazole's adrenal enzyme target with its hepatic drug-metabolizing effect to predict a combined endocrine and pharmacokinetic outcome. Within the adrenal cortex, ketoconazole's most potent inhibitory action is at CYP17A1 (17-alpha-hydroxylase/17,20-lyase), an enzyme that contributes to both cortisol synthesis (via 17-alpha-hydroxylase activity) and androgen synthesis (via 17,20-lyase activity). Inhibiting CYP17A1 therefore lowers both cortisol and adrenal androgens, which can improve androgen-driven manifestations such as hirsutism. Separately, ketoconazole is a strong inhibitor of hepatic CYP3A4; because cyclosporine is a CYP3A4 substrate, ketoconazole markedly raises cyclosporine concentrations, so the cyclosporine dose must be reduced with trough-level monitoring to avoid nephrotoxicity. The integrated prediction is reduced cortisol, reduced androgens with possible hirsutism improvement, and a major increase in cyclosporine exposure requiring dose reduction.
Option A: Option A is incorrect because ketoconazole's most potent target is CYP17A1, not CYP11B1, and it reduces androgens rather than leaving them unchanged; furthermore, ketoconazole inhibits rather than induces CYP3A4, so cyclosporine levels rise and the dose must be reduced, not increased.
Option C: Option C is incorrect because CYP17A1 inhibition lowers rather than raises cortisol and androgens, so hirsutism would tend to improve, not worsen; and CYP3A4 inhibition raises cyclosporine levels, requiring a dose reduction rather than an increase.
Option D: Option D is incorrect because ketoconazole's principal adrenal target is CYP17A1, not aldosterone synthase, and cyclosporine is indeed a CYP3A4 substrate that is strongly affected by ketoconazole, so the claim of no interaction is wrong.
Option E: Option E is incorrect because adrenal androgen synthesis does depend on CYP17A1 (via its 17,20-lyase activity), so hirsutism can improve with ketoconazole; and ketoconazole inhibits rather than induces CYP3A4, so cyclosporine levels rise rather than fall.
10. A 49-year-old woman with established Nelson syndrome after bilateral adrenalectomy has a residual invasive corticotroph adenoma not fully resectable by repeat surgery. Medical therapy with pasireotide or cabergoline is being considered. Integrating the pathophysiology of Nelson syndrome with the corticotroph receptor targets of these agents, which of the following best explains the rationale and the realistic therapeutic goal of medical therapy in this setting?
A) Because Nelson syndrome is driven by autonomous cortisol secretion, the goal of pasireotide or cabergoline is to lower cortisol directly at the adrenal level; this fully controls the syndrome since the adrenal source remains intact.
B) Because the corticotroph adenoma no longer expresses any receptors after adrenalectomy, neither pasireotide nor cabergoline can bind the tumor, so medical therapy has no mechanistic basis and only surgery or radiotherapy can help.
C) Because Nelson syndrome reflects excess mineralocorticoid activity, pasireotide and cabergoline are used to block aldosterone synthesis and control the electrolyte consequences of the syndrome.
D) Nelson syndrome results from loss of cortisol negative feedback after adrenalectomy, driving unopposed ACTH hypersecretion and corticotroph tumor growth; because corticotroph adenomas can express somatostatin receptor subtype 5 (SSTR5) and dopamine D2 receptors (D2R), pasireotide (via SSTR5) and cabergoline (via D2R) can suppress ACTH secretion and may slow tumor activity, with the realistic goal being reduction of ACTH and control of tumor progression rather than restoration of normal feedback (which cannot occur without adrenal glands).
E) Because the patient has no adrenal glands, ACTH is biologically irrelevant, so the only purpose of pasireotide or cabergoline is to treat the hyperpigmentation cosmetically; tumor growth is unaffected by these agents.
ANSWER: D
Rationale:
This question integrates Nelson syndrome pathophysiology with the receptor pharmacology of two corticotroph-directed agents. Nelson syndrome arises after bilateral adrenalectomy: with the adrenal glands removed, cortisol production ceases and the negative feedback that normally restrains ACTH release and limits corticotroph tumor growth is permanently lost, driving unopposed ACTH hypersecretion and tumor expansion. Corticotroph adenomas can express somatostatin receptor subtype 5 (SSTR5) and dopamine D2 receptors (D2R); pasireotide acts through SSTR5 and cabergoline through D2R to suppress ACTH secretion and may help control tumor activity. The realistic therapeutic goal is reduction of ACTH and control of tumor progression — not restoration of normal HPA feedback, which is impossible in the absence of adrenal glands. This integrated reasoning explains both why these agents are mechanistically rational and what they can realistically achieve.
Option A: Option A is incorrect because Nelson syndrome is not driven by autonomous cortisol secretion (the adrenals have been removed), and pasireotide and cabergoline act at the pituitary corticotroph to lower ACTH, not at the adrenal level to lower cortisol.
Option B: Option B is incorrect because corticotroph adenomas do express SSTR5 and D2R, so pasireotide and cabergoline have a clear mechanistic basis; medical therapy is not without a target.
Option C: Option C is incorrect because Nelson syndrome reflects ACTH excess from corticotroph tumor growth, not mineralocorticoid excess, and these agents suppress ACTH rather than blocking aldosterone synthesis.
Option E: Option E is incorrect because ACTH is highly relevant in Nelson syndrome — it drives tumor growth, mass effect, and hyperpigmentation — and suppressing ACTH with these agents can influence tumor activity, so their purpose is not merely cosmetic.
11. A clinician familiar with cabergoline surveillance in prolactinoma (baseline echocardiography recommended above 2 mg per week) is now treating Cushing disease, where the required cabergoline dose is higher. Integrating the receptor basis of cabergoline's valvulopathy risk with the dose difference between the two indications, which of the following best explains how the surveillance principle transfers to the Cushing disease setting?
A) Cabergoline valvulopathy is driven by cumulative exposure at 5-HT2B receptors on valve fibroblasts, independent of indication; because Cushing disease requires higher weekly doses (often 1 to 7 mg/week) than prolactinoma (0.5 to 2 mg/week), cumulative exposure is greater, so the same exposure-based surveillance principle applies and is in fact more pressing — baseline echocardiography is warranted before exceeding 2 mg/week, with periodic monitoring during therapy.
B) Because the valvulopathy is a D2 receptor effect, and corticotroph adenomas express fewer D2 receptors than lactotrophs, the higher Cushing disease doses paradoxically carry lower valve risk, so echocardiographic surveillance can be omitted in Cushing disease.
C) Valvulopathy risk depends only on treatment duration, not dose, so the higher Cushing disease doses do not change the surveillance threshold, and echocardiography is needed only after several years regardless of dose.
D) The valvulopathy risk is specific to prolactinoma physiology and does not transfer to Cushing disease, because the serotonergic environment of a corticotroph adenoma neutralizes 5-HT2B activation at the valve.
E) Because Cushing disease patients receive cabergoline for ACTH suppression rather than prolactin suppression, the drug does not reach cardiac valve tissue, so no echocardiographic surveillance is required at any dose.
ANSWER: A
Rationale:
This question integrates the receptor mechanism of cabergoline valvulopathy with the dose difference between indications to show how a surveillance principle transfers. Cabergoline valvulopathy is mediated by agonism at serotonin 5-HT2B receptors on cardiac valve interstitial fibroblasts, and the risk is driven by cumulative drug exposure — a property of the molecule at the valve that is independent of which pituitary tumor is being treated. Because Cushing disease typically requires higher weekly doses (often 1 to 7 mg/week) than prolactinoma (0.5 to 2 mg/week), cumulative cabergoline exposure is greater, so the exposure-based surveillance principle not only transfers but becomes more pressing: baseline echocardiography is warranted before exceeding 2 mg/week, with periodic surveillance during therapy. The key integrative insight is that valve risk tracks 5-HT2B exposure regardless of the indication or the D2R-mediated therapeutic target.
Option B: Option B is incorrect because valvulopathy is a 5-HT2B effect, not a D2R effect; the density of D2 receptors on the tumor governs therapeutic dose requirements but not valve risk, so higher doses increase rather than decrease cumulative valve exposure.
Option C: Option C is incorrect because valvulopathy risk depends on cumulative exposure (dose and duration together), not duration alone; higher weekly doses raise the exposure and make the surveillance threshold more relevant, not irrelevant.
Option D: Option D is incorrect because the valvulopathy mechanism is a property of cabergoline at cardiac 5-HT2B receptors and is not neutralized by the corticotroph adenoma's environment; the risk transfers to any indication in which cabergoline is used.
Option E: Option E is incorrect because cabergoline is a systemically distributed drug that reaches cardiac valve tissue regardless of the pituitary target it is being used to suppress; the indication does not change its biodistribution, so surveillance remains warranted at higher doses.
12. A 54-year-old man with acromegaly has persistently elevated insulin-like growth factor-1 (IGF-1) on a maximum-dose first-generation somatostatin analog (SSA). His serum prolactin is elevated. Integrating the receptor biology of somatotroph adenomas with the significance of the elevated prolactin, which of the following best predicts his likely response to adding cabergoline and explains the mechanism?
A) The elevated prolactin indicates pure prolactinoma physiology, so cabergoline will normalize both prolactin and IGF-1 by acting on lactotrophs, and the SSA can be discontinued.
B) Somatotroph adenomas express only D2 receptors, so cabergoline is more effective than the SSA, and the elevated prolactin is irrelevant to predicting response.
C) Somatotroph adenomas predominantly express somatostatin receptors (SSTR2 and SSTR5), which is why the SSA is the mainstay, but a subset are mixed lactosomatotroph tumors that also express dopamine D2 receptors (D2R); the elevated prolactin is a clinical marker suggesting D2R expression, so adding cabergoline (acting via D2R) is more likely to produce additive IGF-1 reduction in this patient than in an acromegaly patient with normal prolactin.
D) The elevated prolactin reflects stalk compression unrelated to receptor expression, so it provides no information about likely cabergoline response, and adding cabergoline is no more likely to help than in any other patient.
E) Cabergoline lowers IGF-1 by inhibiting hepatic IGF-1 synthesis directly, independent of any pituitary receptor, so the elevated prolactin and tumor receptor expression are irrelevant to predicting response.
ANSWER: C
Rationale:
This question integrates somatotroph receptor biology with the predictive value of elevated prolactin. Most somatotroph adenomas predominantly express somatostatin receptors (SSTR2 and SSTR5), which is why first-generation SSAs are the mainstay of medical therapy and dopamine agonists are generally weaker. However, a subset are mixed lactosomatotroph tumors that co-secrete growth hormone and prolactin and that also express dopamine D2 receptors (D2R). In this context, an elevated serum prolactin is a useful clinical marker suggesting D2R expression on the tumor; published series show that acromegaly patients with elevated prolactin (or with only mildly elevated IGF-1) are more likely to achieve additive IGF-1 reduction when cabergoline is added to an SSA. The integrated prediction is that adding cabergoline is more likely to help this patient — whose prolactin is elevated — than an acromegaly patient with normal prolactin.
Option A: Option A is incorrect because the elevated prolactin indicates a mixed lactosomatotroph tumor rather than a pure prolactinoma; the dominant clinical disease is acromegaly, cabergoline produces only modest IGF-1 effects, and the SSA should not simply be discontinued.
Option B: Option B is incorrect because somatotroph adenomas predominantly express somatostatin receptors, not only D2 receptors; the SSA is the mainstay, and the elevated prolactin is in fact relevant — it predicts a higher chance of dopaminergic response.
Option D: Option D is incorrect because in this setting elevated prolactin reflects co-secretion from a mixed tumor expressing D2R rather than mere stalk-compression disconnection, and it does carry predictive value for cabergoline response.
Option E: Option E is incorrect because cabergoline does not directly inhibit hepatic IGF-1 synthesis; it acts at pituitary D2 receptors to reduce growth hormone secretion from D2R-expressing tumors, so tumor receptor expression and the prolactin marker are central to predicting response.
13. A clinician is constructing a unified monitoring plan for patients on different adrenal steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat, mitotane) used in Cushing disease. Integrating the shared class risk with the agent-specific mechanisms, which of the following best captures both the common safety thread and the agent-specific monitoring that must be layered on top of it?
A) The only shared risk across the class is hepatotoxicity, so liver function tests alone are sufficient monitoring for every agent, and no agent-specific monitoring is required.
B) The shared class risk is adrenal insufficiency as cortisol is lowered toward or below normal — so every patient needs education on adrenal insufficiency symptoms and access to stress-dose hydrocortisone; layered on top, agent-specific monitoring differs: ketoconazole requires liver function tests and QT surveillance (strong CYP3A4 inhibitor with many interactions); metyrapone requires watching for DOC-driven hypertension and hypokalemia; osilodrostat requires electrolytes, blood pressure, and QT monitoring (CYP11B2 inhibition lowering aldosterone, plus CYP2D6 interactions); and mitotane requires lifelong glucocorticoid and mineralocorticoid replacement plus management of its potent CYP3A4/CYP2B6 induction (e.g., warfarin and steroid dose increases).
C) The shared class risk is hyperglycemia from somatostatin receptor activation, so all four agents are monitored with HbA1c; no other monitoring differences exist among them.
D) There is no shared class risk; each agent is monitored only for its unique toxicity, and adrenal insufficiency is not a concern because ACTH rises and maintains cortisol in all cases.
E) The shared class risk is cardiac valvulopathy from 5-HT2B activation, so all four agents require baseline and periodic echocardiography, with no need for agent-specific laboratory monitoring.
ANSWER: B
Rationale:
This question integrates the common safety thread shared by all adrenal steroidogenesis inhibitors with the distinct mechanisms that require agent-specific monitoring. The shared class risk is adrenal insufficiency: every effective steroidogenesis inhibitor lowers cortisol, and as cortisol falls toward or below normal, patients accustomed to cortisol excess can become symptomatic — so all patients require education on adrenal insufficiency symptoms and access to stress-dose hydrocortisone. Layered on top of this common thread, each agent carries distinct monitoring needs tied to its mechanism: ketoconazole requires liver function tests (hepatotoxicity) and QT surveillance, and carries extensive CYP3A4 inhibition interactions; metyrapone requires watching for DOC-driven hypertension and hypokalemia (proximal CYP11B1 block); osilodrostat requires electrolyte, blood pressure, and QT monitoring because CYP11B2 inhibition lowers aldosterone, plus attention to CYP2D6 interactions; and mitotane requires lifelong glucocorticoid and mineralocorticoid replacement (adrenal destruction) plus management of its potent CYP3A4 and CYP2B6 induction (for example, increased warfarin and steroid doses). This layered framework captures both the unifying risk and the agent-specific surveillance.
Option A: Option A is incorrect because hepatotoxicity is specific to ketoconazole rather than a universal class risk, and agent-specific monitoring is clearly required; liver function tests alone are insufficient for the class.
Option C: Option C is incorrect because hyperglycemia from somatostatin receptor activation is a feature of pasireotide, not of the steroidogenesis inhibitor class; these agents do not act through somatostatin receptors, and monitoring differences among them are substantial.
Option D: Option D is incorrect because there is a strong shared class risk — adrenal insufficiency — and although ACTH rises as cortisol falls, the adrenal target is being pharmacologically inhibited (or destroyed, with mitotane), so rising ACTH does not maintain cortisol and adrenal insufficiency remains a genuine concern.
Option E: Option E is incorrect because cardiac valvulopathy from 5-HT2B activation is a property of cabergoline, not of the steroidogenesis inhibitor class; echocardiography is not the unifying monitoring requirement, and agent-specific laboratory monitoring is essential.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.